BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 11950687)

  • 21. APC resistance: biological basis and acquired influences.
    Castoldi E; Rosing J
    J Thromb Haemost; 2010 Mar; 8(3):445-53. PubMed ID: 20002539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endogenous factor V synthesis in megakaryocytes contributes negligibly to the platelet factor V pool.
    Thomassen MC; Castoldi E; Tans G; Magdeleyns EJ; Delaunoit C; Debusscher L; Van Assche KJ; Rosing J
    Haematologica; 2003 Oct; 88(10):1150-6. PubMed ID: 14555311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factor V and protein S as cofactors to activated protein C.
    Dahlbäck B
    Haematologica; 1997; 82(1):91-5. PubMed ID: 9107093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation.
    Brugge JM; Simioni P; Bernardi F; Tormene D; Lunghi B; Tans G; Pagnan A; Rosing J; Castoldi E
    J Thromb Haemost; 2005 Dec; 3(12):2695-702. PubMed ID: 16359508
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional characterization of recombinant FV Hong Kong and FV Cambridge.
    Norstrøm E; Thorelli E; Dahlbäck B
    Blood; 2002 Jul; 100(2):524-30. PubMed ID: 12091344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impaired factor V-related anticoagulant mechanisms and deep vein thrombosis associated with A2086D and W1920R mutations.
    Shimonishi N; Ogiwara K; Yoshida J; Horie K; Nakajima Y; Furukawa S; Takeyama M; Nogami K
    Blood Adv; 2023 Jun; 7(12):2831-2842. PubMed ID: 36780344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prothrombin amino terminal region helps protect coagulation factor Va from proteolytic inactivation by activated protein C.
    Yegneswaran S; Nguyen PM; Gale AJ; Griffin JH
    Thromb Haemost; 2009 Jan; 101(1):55-61. PubMed ID: 19132189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factor V Has Anticoagulant Activity in Plasma in the Presence of TFPIα: Difference between FV1 and FV2.
    van Doorn P; Rosing J; Duckers C; Hackeng TM; Simioni P; Castoldi E
    Thromb Haemost; 2018 Jul; 118(7):1194-1202. PubMed ID: 29864781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factor V has an anticoagulant cofactor activity that targets the early phase of coagulation.
    Santamaria S; Reglińska-Matveyev N; Gierula M; Camire RM; Crawley JTB; Lane DA; Ahnström J
    J Biol Chem; 2017 Jun; 292(22):9335-9344. PubMed ID: 28420729
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel insights into the regulation of coagulation by factor V isoforms, tissue factor pathway inhibitorα, and protein S.
    Dahlbäck B
    J Thromb Haemost; 2017 Jul; 15(7):1241-1250. PubMed ID: 28671348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Congenital and acquired activated protein C resistance.
    Nicolaes GA; Dahlbäck B
    Semin Vasc Med; 2003 Feb; 3(1):33-46. PubMed ID: 15199491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peptidomimetic inhibitors for activated protein C: implications for hemophilia management.
    Butenas S; Orfeo T; Kalafatis M; Mann KG
    J Thromb Haemost; 2006 Nov; 4(11):2411-6. PubMed ID: 17059471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amino acid region 1000-1008 of factor V is a dynamic regulator for the emergence of procoagulant activity.
    Wiencek JR; Na M; Hirbawi J; Kalafatis M
    J Biol Chem; 2013 Dec; 288(52):37026-38. PubMed ID: 24178294
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factor V: Dr. Jeckyll and Mr. Hyde.
    Kalafatis M; Mann KG
    Adv Exp Med Biol; 2001; 489():31-43. PubMed ID: 11554589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulation of factor V and factor V-short by TFPIα: Relationship between B-domain proteolysis and binding.
    Petrillo T; Ayombil F; Van't Veer C; Camire RM
    J Biol Chem; 2021; 296():100234. PubMed ID: 33376137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of prothrombin on the individual activated protein C-mediated cleavages of coagulation factor Va.
    Tran S; Norstrøm E; Dahlbäck B
    J Biol Chem; 2008 Mar; 283(11):6648-55. PubMed ID: 18198180
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural investigation of the A domains of human blood coagulation factor V by molecular modeling.
    Villoutreix BO; Dahlbäck B
    Protein Sci; 1998 Jun; 7(6):1317-25. PubMed ID: 9655335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early days of APC resistance and FV Leiden.
    Dahlbäck B
    Hamostaseologie; 2008; 28(3):103-9. PubMed ID: 18521487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factor Xa activation of factor V is of paramount importance in initiating the coagulation system: lessons from a tick salivary protein.
    Schuijt TJ; Bakhtiari K; Daffre S; Deponte K; Wielders SJ; Marquart JA; Hovius JW; van der Poll T; Fikrig E; Bunce MW; Camire RM; Nicolaes GA; Meijers JC; van 't Veer C
    Circulation; 2013 Jul; 128(3):254-66. PubMed ID: 23817575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The anticoagulant function of coagulation factor V.
    Cramer TJ; Gale AJ
    Thromb Haemost; 2012 Jan; 107(1):15-21. PubMed ID: 22116556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.